Eastern asian expert panel opinion

Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma

Winnie Yeo, Pei Jer Chen, Junji Furuse, KwangHyub Han, Chiun Hsu, Ho Yeong Lim, Hanlim Moon, Shukui Qin, Ee Min Yeoh, Sheng Long Ye

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as portal hypertension can be better defined with standardized methodology. Consensus in treatment must be sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia. Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease.

Original languageEnglish
Article number620
JournalBMC cancer
Volume10
DOIs
Publication statusPublished - 2010 Nov 10

Fingerprint

Molecular Targeted Therapy
Expert Testimony
Hepatocellular Carcinoma
Clinical Trials
Neoplasm Staging
Portal Hypertension
Virus Diseases
Liver Neoplasms
Disease Management
Hepatitis B virus
Antiviral Agents
Therapeutics
Research
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Yeo, Winnie ; Chen, Pei Jer ; Furuse, Junji ; Han, KwangHyub ; Hsu, Chiun ; Lim, Ho Yeong ; Moon, Hanlim ; Qin, Shukui ; Yeoh, Ee Min ; Ye, Sheng Long. / Eastern asian expert panel opinion : Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. In: BMC cancer. 2010 ; Vol. 10.
@article{0ac5fbb3015b42329cd022d689a7eae5,
title = "Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma",
abstract = "The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as portal hypertension can be better defined with standardized methodology. Consensus in treatment must be sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia. Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease.",
author = "Winnie Yeo and Chen, {Pei Jer} and Junji Furuse and KwangHyub Han and Chiun Hsu and Lim, {Ho Yeong} and Hanlim Moon and Shukui Qin and Yeoh, {Ee Min} and Ye, {Sheng Long}",
year = "2010",
month = "11",
day = "10",
doi = "10.1186/1471-2407-10-620",
language = "English",
volume = "10",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

Eastern asian expert panel opinion : Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma. / Yeo, Winnie; Chen, Pei Jer; Furuse, Junji; Han, KwangHyub; Hsu, Chiun; Lim, Ho Yeong; Moon, Hanlim; Qin, Shukui; Yeoh, Ee Min; Ye, Sheng Long.

In: BMC cancer, Vol. 10, 620, 10.11.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Eastern asian expert panel opinion

T2 - Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma

AU - Yeo, Winnie

AU - Chen, Pei Jer

AU - Furuse, Junji

AU - Han, KwangHyub

AU - Hsu, Chiun

AU - Lim, Ho Yeong

AU - Moon, Hanlim

AU - Qin, Shukui

AU - Yeoh, Ee Min

AU - Ye, Sheng Long

PY - 2010/11/10

Y1 - 2010/11/10

N2 - The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as portal hypertension can be better defined with standardized methodology. Consensus in treatment must be sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia. Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease.

AB - The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as portal hypertension can be better defined with standardized methodology. Consensus in treatment must be sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia. Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease.

UR - http://www.scopus.com/inward/record.url?scp=78149265063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149265063&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-10-620

DO - 10.1186/1471-2407-10-620

M3 - Article

VL - 10

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 620

ER -